Why Academic Medical Centers Should Ban Drug Company Gifts to Individuals

American Journal of Bioethics 10 (1):13-15 (2010)
  Copy   BIBTEX

Abstract

This article has no associated abstract. (fix it)

Categories

Keywords

Reprint years

DOI

10.1080/15265160903441061

Other Versions

No versions found

Links

PhilArchive



    Upload a copy of this work     Papers currently archived: 100,937

External links

Setup an account with your affiliations in order to access resources via your University's proxy server

Through your library

My notes

Similar books and articles

Drug Detailing in Academic Medical Centers: Regulating for the Right Reasons, with the Right Evidence, at the Right Time.Michael Steinman & Dean Schillinger - 2010 - American Journal of Bioethics 10 (1):21-23.
Drug Detailers, Professionalism, and Prudence.Howard Brody - 2010 - American Journal of Bioethics 10 (1):9-10.
The Pitfalls of Deducing Ethics From Behavioral Economics: Why the Association of American Medical Colleges Is Wrong About Pharmaceutical Detailing.Thomas S. Huddle - 2010 - American Journal of Bioethics 10 (1):1-8.
Cheap Trinkets, Effective Marketing: Small Gifts from Drug Companies to Physicians.Allan S. Brett - 2003 - American Journal of Bioethics 3 (3):52-54.
Pharmaceutical “Gift-Giving,” Medical Education, and Conflict of Interest.Dale Murray & Heather Certain - 2007 - Journal of Philosophical Research 32 (9999):335-343.
Talking at Cross Purposes: Why We Shouldn’t Re-Establish the Relationship Between Theological and Secular Bioethics.Heidi Matisonn - 2020 - American Journal of Bioethics 20 (12):45-47.
Attitudes of Future Doctors of Bangladesh to Pharmaceutical Incentives and Medical Ethics.Tonmoy Biswas & Darryl Macer - 2017 - Eubios Journal of Asian and International Bioethics 27 (3):70-80.
All Gifts Large and Small.Dana Katz, Arthur L. Caplan & Jon F. Merz - 2003 - American Journal of Bioethics 3 (3):39-46.
Why Insurance Companies Should Pay for Medical Cannabis.David Casarett & Donald I. Abrams - 2019 - American Journal of Bioethics 19 (4):8-10.
Access to Medication and Drug Company Sales Practices: Setting Priorities for Critique and Advocacy.Naomi Seiler - 2003 - American Journal of Bioethics 3 (3):61-61.

Analytics

Added to PP
2010-09-14

Downloads
38 (#593,075)

6 months
11 (#345,260)

Historical graph of downloads
How can I increase my downloads?

Citations of this work

Add more citations

References found in this work

Lunch with Lilly: Who Pays?Carson Strong - 2003 - American Journal of Bioethics 3 (3):62-63.

Add more references